SYNE2

Across TCGA pan-cancer cohorts, SYNE2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SYNE2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SYNE2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SYNE2 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, LSCC, and HNSC are the cancer types where SYNE2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SYNE2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	IV	−0.890	<.001	12	view →
LSCC	All	III,IV	+0.483	<.001	8	view →
HNSC	Male	II,III,IV	+0.293	<.001	7	view →
COAD	All	All	−0.064	.010	6	view →
PDAC	All	II,III,IV	+0.196	.009	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SYNE2–CCRCC

Open the CCRCC breakdown →